Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco.24.00727 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Adi Diab und 24 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Melanoma, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols, Skin Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
PURPOSE There are limited treatment options for advanced melanoma that have progressed during or after immune checkpoint inhibitor therapy. Intratumoral (IT) immunotherapy may improve tumor-specific immune activation by promoting local tumor antigen presentation while avoiding systemic toxicities. The phase 3 ILLUMINATE-301 study (ClinicalTrials.gov identifier: NCT03445533 ) evaluated tilsotolimod, a Toll-like receptor-9 agonist, with or without ipilimumab in patients with anti–PD-1 advanced refractory melanoma. METHODS Patients with unresectable stage III-IV melanoma that progressed during or after anti–PD-1 therapy were randomly assigned 1:1 to receive 24 weeks of tilsotolimod plus ipilimumab or 10 weeks of ipilimumab alone. Nine IT injections of tilsotolimod were administered to a single designated lesion over 24 weeks. Intravenous ipilimumab 3 mg/kg was administered once every 3 weeks from week 2 in the tilsotolimod arm and week 1 in the ipilimumab arm. The primary end point was efficacy measured using objective response rate (ORR; independent review) and overall survival (OS). RESULTS A total of 481 patients received tilsotolimod plus ipilimumab (n = 238) or ipilimumab alone (n = 243). ORRs were 8.8% in the tilsotolimod arm and 8.6% in the ipilimumab arm, with disease control rates of 34.5% and 27.2%, respectively. Median OS was 11.6 months in the tilsotolimod arm and 10 months in the ipilimumab arm (hazard ratio, 0.96 [95% CI, 0.77 to 1.19]; P = .7). Grade ≥3 treatment-emergent adverse events occurred in 61.1% and 55.5% of patients in the tilsotolimod and ipilimumab arms, respectively. CONCLUSION Combining IT tilsotolimod with ipilimumab did not significantly improve the ORR or OS compared with ipilimumab alone in patients with anti–PD-1 advanced refractory melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Melanoma Cancer Immunotherapy and Development Therapeutics Unit Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale," Napoli, Italy.
- Italy and Center for Immuno-Oncology, Azienda Ospedaliero Universitlaria Senese, University of Siena, Siena, Italy.
- Clinical Oncology Department, Assiut University, Assiut, Egypt.
- Centre Léon Bérard Lyon, University Lyon I, Lyon, France.
- Inserm U1189, CHU Lille, University of Lille, Lille, France.
ORCID-Profile: Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Petr Arenberger, Ivana Krajsova, Luis de la Cruz, Celeste Lebbe, Jean-Jacques Grob, Marcus O Butler, Sebastian Haferkamp, Massimo Guidoboni, Caroline Robert
Zitieren
APA
Diab, A., Ascierto, P. A., Maio, M., Abdel-Wahab, R., Negrier, S., Mortier, L., Arenberger, P., Dalle, S., Krajsova, I., de la Cruz, L., Leccia, M. T., Guida, M., Lebbe, C., Grob, J. J., Butler, M. O., In, G. K., Loquai, C., Walker, J. W. T., Atkinson, V., …, & Robert, C. (2025). Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00727
Vancouver
Diab A, Ascierto PA, Maio M, Abdel-Wahab R, Negrier S, Mortier L, et al. Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00727
BibTeX
@article{Diab2025,
author = {Diab, Adi and Ascierto, Paolo A and Maio, Michele and Abdel-Wahab, Reham and Negrier, Sylvie and Mortier, Laurent and Arenberger, Petr and Dalle, Stephane and Krajsova, Ivana and de la Cruz, Luis and Leccia, Marie-Therese and Guida, Michele and Lebbe, Celeste and Grob, Jean-Jacques and Butler, Marcus O and In, Gino K and Loquai, Carmen and Walker, John W T and Atkinson, Victoria and Kapiteijn, Ellen and Haferkamp, Sebastian and Chunduru, Srinivas and Rahimian, Shahram and Guidoboni, Massimo and Robert, Caroline},
title = {Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.24.00727}
}
EUVIMED